Administering recombinant IL-1 receptor antagonist or monoclonal antibodies against TNF-α or IL-6 or their receptors has proved beneficial in clinical therapy of patients with rheumatoid arthritis [4,5,6]. Here, IL6 is linked to rheumatoid arthritis.